Dr Thomas Roth Gives His Opinion About The Most Important Advance in Insomnia Pathology
In this video, Thomas Roth, PhD, Professor, Department of Psychiatry, Wayne State University School of Medicine, provides his option on the most important advance in our understanding of insomnia pathology in recent years.
This video was taken on June 3, 2013, at the Sleep 2013 Conference in Baltimore, MD.
Early this week, Novation, a healthcare services company that oversees supply chain management, called on Genentech to reverse its decision to use only specialty drug distributors instead of wholesale distributors for its widely used anticancer treatments, Avastin, Rituxan, and Herceptin.
The call for value-based care is propelled by the shortage of family physicians and the disparity connection between the time it takes to care for the sickest patients and what Medicare and Medicaid pay. A study in this month’s issue of The American Journal of Managed Care tracks just how bad things are, by looking at a normal day in a family practice.
Authors in the New England Journal of Medicine discuss the prospects and pitfalls of implementing a new CMS fee for physicians who coordinate care for Medicare patients with multiple chronic conditions.
Eric C. Schneider, MD, senior principal researcher and distinguished chair in health care quality at RAND, and director of its Boston office, will join The Commonwealth Fund as senior vice president for policy and research on February 2, 2015.
The ACO and Emerging Healthcare Delivery Coalition, an initiative of The American Journal of Managed Care, held its most recent WebEx session this week. Participants discussed new strategies and technologies that both employers and healthcare organizations can use to get patients to take ownership over their own care.
Amid last week's news that CMS had miscalculated the number of enrollees under the Affordable Care Act was a quieter announcement that the agency had appointed a chief data office to improve transparency, among other tasks.
Genentech's decision to use a handful of specialty drug distributors instead of wholesalers for the distribution of the most commonly used anticancer medications has raised concerns of availability and cost.